Stay updated on Atezolizumab Combo in Esophageal Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab Combo in Esophageal Carcinoma Clinical Trial page.

Latest updates to the Atezolizumab Combo in Esophageal Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1 while the study record page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now renders a 403 Forbidden error, replacing the usual study record content with an error screen and preventing access to the trial's details on that page.SummaryDifference18%

- Check46 days agoChange DetectedThe page now states there are 67 participating locations. It also updates the outcomes section to specify IRF-assessed PFS and OS with defined criteria, adds CRS grading and quality-of-life/AE measures, and introduces an IPD data-sharing plan with related documents.SummaryDifference2%

- Check67 days agoChange DetectedThe page revision tag was updated from v3.6.4 to v3.6.5. This denotes a new page version without substantive changes to the study data or its presentation.SummaryDifference0.0%

- Check81 days agoChange DetectedNew page revision entry v3.6.4 has been added to the revision history, indicating a minor update to the page. The previous revision v3.6.3 has been removed from the history.SummaryDifference0.0%

- Check102 days agoChange Detected**A new page revision tag, v3.6.3, was added and the previous tag, v3.6.2, was removed. This reflects a minor update to the page's revision history.**SummaryDifference0.0%

Stay in the know with updates to Atezolizumab Combo in Esophageal Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab Combo in Esophageal Carcinoma Clinical Trial page.